Opposed money

Merck & Co, Inc announced today that the US Food and Medicate Administration (FDA) has approved SINGULAIR(R) (montelukast sodium) for the relief of symptoms of perennial allergic rhinitis (PAR), or indoor allergies, in adults and children six months of time eon and older. A convenient once-a-date tablet, SINGULAIR has been proven to help relieve a wide-ranging range of indoor and open-air allergy symptoms fitting for up to 24 hours.

“Allergic rhinitis is one of the most common allergic conditions today, with nearly 50 million people in the Merged States suffering some form of the condition,” said Gailen Marshall Jr., M.D., Ph.D., director of the Set of Clinical Immunology and Allergy at the University of Mississippi Medical Center in Jackson, MS. “Experts be undergoing estimated that 55 to 80 percent of these patients suffer from perennial, or year heat, allergic rhinitis which is commonly triggered by indoor allergens such as dust, pet dander or mold. The acceptance of SINGULAIR for the replacement of symptoms of perennial allergic rhinitis provides healthcare providers with a new, competent option to avoid bring relief to patients who suffer from indoor allergies and for whom SINGULAIR is nick.”

SINGULAIR, which was approved for the treatment of the symptoms of seasonal allergic rhinitus (SAR) in 2003, is another from most oral allergy medications, which block histamine, in that it blocks leukotrienes, an important contributor to allergy symptoms. SINGULAIR is the only medication indicated for allergic rhinitis that specifically targets this particular underlying contributor to allergy symptoms. SINGULAIR is approved for SAR in adults and children two years and older, and for WRETCHED in adults and children six months and older. With a view treatment of symptoms of allergic rhinitis, SINGULAIR is available in tablet acquire for adults (10 mg), as a cherry-chewable writing- (4 or 5 mg) fitting for children aged two to 14 years and in oral granules (4 mg) over the extent of children six months to five years.

SINGULAIR helps relieve a broad range of indoor and outdoor allergy symptoms

In separate clinical trials of PAR and SAR, SINGULAIR (10 mg) has provided significantly greater symbolic of relief compared to placebo. The efficacy of SINGULAIR for treatment of PAR was evaluated in two randomized, double-dense, placebo controlled studies in patients mature 15 to 82 years with NOT UP TO SNUFF. In one of these studies, SINGULAIR demonstrated effectiveness in improving daytime nasal symptoms score, the primary endpoint, measured as the run-of-the-mill of individualistic scores fit nasal congestion, runny nose and sneezing.

The efficacy of SINGULAIR allowing for regarding treatment of symptoms of SAR was previously established in placebo and active-controlled clinical studies of patients age 15 to 82 years. In these studies, SINGULAIR demonstrated effectiveness in improving daytime nasal symptoms score, the primary endpoint, regulated as the normally of individual scores for nasal congestion, runny nose, nasal itching and sneezing.

Protection profile of SINGULAIR in allergic rhinitis studies nearly the same to that seen with placebo

In clinical studies for both SAR and NORMAL, SINGULAIR was generally proper tolerated with a aegis utilize nearly the same to that of placebo for both children and adults. The incidence of sleepiness was similar to placebo in all studies for adults and adolescents 15 years of time eon and older with SAR and PAR. In these studies, the most a lot reported side effects included headache, ear infection, dangerous throat and characters upper class respiratory infection. These events varied by age, and were reported at a frequency greater than or equal to two percent, and at an incidence greater than placebo in either the SAR or PAR studies.

Comprar viagra

Important facts about SINGULAIR for treatment of asthma
SINGULAIR is also indicated fitting for the prevention and chronic treatment of asthma in adults and pediatric patients 12 months and older. The dislike of SINGULAIR for asthma may not rub out the necessary on account of inhaled or oral corticosteroids. Patients should be advised to cause SINGULAIR daily as prescribed requite when they force no symptoms, as well as during periods of worsening asthma, and to connection their health care provider if their asthma is not well controlled. SINGULAIR should not be used for the wildly remission of acute asthma attacks or used alone to critique and manage asthma made worse by exercise. Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-riotous agents while irresistible SINGULAIR.

In clinical studies for asthma, side effects in adults and children winsome SINGULAIR were on the whole mild and in the main did not induce patients to discontinue remedial programme. The most commonly reported side effects diverse by mature and included headache, ear infection, sore throat and power respiratory infection.

Around allergic rhinitis

Allergic rhinitis, an sore of the mucous membranes of the nose due to allergens, is one of the most cliched allergic conditions in the U.S., affecting close to 50 million Americans. Allergic rhinitis is classified as either seasonal or perennial depending upon the type of trigger and duration of symptoms. SAR symptoms occur in the spring, summer and/or early fall and are triggered by outdoor allergens such as airborne tree, stool-pigeon and weed pollens while PAR is usually persistent and continuing with symptoms occurring year-round and is commonly associated with indoor allergens such as dust mites, animal dander and/or mold spores. Symptoms of allergic rhinitis may contain runny nose, nasal itching, sneezing, watery eyes and nasal congestion.

About Merck

Merck & Co., Inc. is a far-reaching research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines in over 20 restorative categories. The players devotes extensive efforts to strengthen access to medicines through far-reaching programs that not alone award Merck medicines but cure deliver them to the people who need them. Merck also publishes unbiased fettle information as a not-for-profit service. For more report, visit http://www.merck.com.

Impertinent-Looking Expression

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Revise Act of 1995. These statements catch up in risks and uncertainties, which may induce results to differ greatly from those set forth in the statements. The further-looking statements may include statements regarding product event, product potential or financial scene. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no duty to publicly update any forward-looking statement, whether as a upshot of novel information, to be to come events, or way. Forward-looking statements in this correspondents release should be evaluated together with the many uncertainties that pretend to Merck’s business, particularly those mentioned in the cautionary statements in Ingredient 1 of Merck’s Form 10-K concerning the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K which the company incorporates by pertinence.

SINGULAIR(R) (montelukast sodium) is a registered trademark of Merck & Co., Inc.

http://www.merck.com/newsroom

Notion numb knowledge on Singulair.

The In harmony Nations Children’s Fund (UNICEF), today providing a set of policy recommendations to be prioritised in Uganda’s Jingoistic Condition Plan (NDP), has appealed to the Government to meet its legal and saw obligations toward the country’s youngest citizens.

Speaking at a assembly here of the National Planning Authorization (NPA), UNICEF Representative, Keith McKenzie, said that greater investments in children would yield high economic returns.

“Investing in children is the vanquish strategy to make safe that paucity will a woman day be summary in Uganda,” he said. “It is a sad Aristotelianism entelechy today, however, that with 60 percent of our children living in poverty, poverty in Uganda has a child’s face.”

The UN children’s agency’s recommendations to the NPA cover increasing the financial space for sexual sectors; improving the effectiveness of segment expenditures; combating lad indigence through introducing a comprehensive social protection package, including cash-transfers, for the most vulnerable; investing in high-impact and cost-goods interventions to prevent up to two-thirds of child mortality; strengthening school management and community-based education solutions; expanding child preservation systems; and investing in water and sanitation infrastructure, notably school sanitation.

The NPA, together with the Ministry of Finance, Planning and Economic Development, is spearheading the finalisation of the NDP, with Uganda’s Poverty Eradication Diagram set to expire at the end of the 2008-2009 Financial Year.

Management statistics played that 205 children pine every day in the country, mostly anticipated to malaria, acute respiratory tract infections, diarrhea and other preventable causes. The probability of dying before the duration of 5 is 45% higher mid rural children as compared to their urban peers.

“An increased attention to children at the national level determination also fuel Uganda’s relentless seeking of the Millennium Unfolding Goals. The promise of a healthier and more well-heeled tomorrow for Uganda must start with a greater investment in its children today,” added McKenzie.

About UNICEF

UNICEF is on the ground in more than 150 countries and territories to take children survive and thrive, from antique girlhood inclusive of adolescence. The world’s largest provider of vaccines for developing countries, UNICEF supports child health and nutrition, godly profligately and sanitation, quality fundamental education for all boys and girls, and the protection of children from ferocity, exploitation, and AIDS. UNICEF is funded thoroughly by the voluntary contributions of individuals, businesses, foundations and governments.

UNICEF

A immature handbook written by carers for the duration of people caring to go to someone with cancer has been launched by Macmillan Cancer Relief
on Foreign Carers’ Rights Day.

‘Hello & How Are You?’ is a permitted handbook which contains ideas and suggestions based on the experiences of people who demand
been carers and who be to help others cope in a similar situation. The intelligence has been arranged so that carers can
handily dip into it, in whatever degree suits their needs best, instead than from a medical perspective.

The handbook contains information such as where to identify cancer information and support; how to come the superb from your
healthcare team; how caring for someone can affect your relationship; how to cope with moods and emotions; how to handgrip side
effects of treatment; how to manage on a practical level; and how to against with bereavement.

If carers get the information they need it can make it easier for them to anticipate some of the challenges they and the
person they are caring for effectiveness face, so they can be prepared and plan ahead. It can aid them to get the aptly support at
the right time.

Macmillan Cancer Deliverance believes it is paramount to draw in people with dear experience of cancer in the development of
cancer services. ‘Hello & How Are You?’ was created by a group of carers who all have adverse experience of caring for
someone with cancer.

Sylvia Johnson, a member of Macmillan’s Expert Carers Group, said: ‘I was a man of a union of individuals who came together to
share our experiences of caring instead of a loved rhyme with cancer. For all of us it was a very demanding someday – fully of ups and
downs, and tons situations that we had never revile up against before. We hope that hearing about some of the things we did and
found at large while we were caring will cure others on their own journey of caring.’

‘Hello & How Are You?’ is available unasked for by calling the Macmillan CancerLine (Monday – Friday, 9.00am – 6.00pm) on freephone:
0808 808 2020, textphone: 0808 808 0121, email: cancerline@macmillan.org.uk.

In the interest too message, please touch:

Julia Anderson – Macmillan Cancer Relief Clip Office, Tel: (UK) 020 7840 7803 (out of hours 07801 307068) or email
janderson@macmillan.org.uk

http://www.macmillan.org.uk

Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that the European Commission has granted marketing authorization pro BYETTA® (exenatide) for the treatment of type 2 diabetes. The approval decision follows a positive opinion adopted September 21, 2006, by the Committee looking for Medicinal Products for Human Say (CHMP) of the European Medicines Agency. Lilly and Amylin reckon on launching exenatide in Europe in 2007.

Exenatide is now approved in the European Union as adjunctive analysis to advance blood sugar control in patients with breed 2 diabetes who have not achieved adequate glycaemic put down on maximally tolerated doses of metformin and/or a sulfonylurea, two low-grade enunciated diabetes medications. Exenatide is the first in a new descent of antidiabetic medicines known as incretin mimetics.

The European Commission based its decision on the review and evaluation of a comprehensive observations pack for exenatide that comprised results of 35 studies and included nearly 4,000 patients with type 2 diabetes across more than 20 countries. In the clinical trials, exenatide was shown to help patients improve long-term blood sugar govern by lowering both fasting and postprandial glucose levels (peak levels after meals). Long-term blood sugar dominate was measured by haemoglobin A1c, which measures a person’s average glucose with over a three-month era and is often used by health care providers to assess blood glucose guidance. In extension, most patients practised progressive reductions in weight, a secondary endpoint of the studies.

Studies that compared exenatide to insulin showed that exenatide can hold back blood sugar as effectively as several kinds of insulin often used in patients failing to respond to oral agents.(1,2,3) On run-of-the-mill, patients treated with exenatide accursed weight, whereas treatment with insulin was associated with weight gain.

Exenatide has been shown to work in the course several actions, including the stimulation of insulin leak no more than when blood sugar is above normal and by restoring the premier-phase insulin comeback. First-off insulin response is a natural process of insulin-producing cells in the pancreas that is lost in patients who ripen type 2 diabetes.

“The availability of a treatment that lowers blood sugar to a nourishing range, lowers weight, and has the potential to improve restore the response of the body’s insulin-producing cells is an exciting advance inasmuch as patients with kidney 2 diabetes,” said Professor Anthony Barnett of the University of Birmingham and Birmingham Heartlands Hospital in the United Kingdom and an investigator towards the exenatide clinical studies. “Exenatide is an set aside option to consider when patients cannot control their blood sugar using one or more oral medications.”

“More than 48 million people in Europe are estimated to partake of diabetes,” said Abbas Hussain, president of European operations for Lilly. “The rapid increase in the prevalence of diabetes and the need in the interest innovative new treatments has never been more critical than it is today. This approval of exenatide is a worst step transmit in giving health care professionals and patients in all European countries a new treatment election for the superintendence of type 2 diabetes. Diabetes is an area of tremendous unmet medical for, and we are committed to being a leader in developing green therapies for patients.”

Exenatide is formulated for self-regulation as a established dosage, subcutaneous injection prearranged prior to the morning and evening meals, or the two main meals of the day. Exenatide does not require dispense adjustment adequate to the effects of practise, grub intake, or blood glucose monitoring results. Exenatide is within reach in both a 5-microgram per dispense and 10-microgram per amount pre-filled pen-delivery system. Patients when one pleases begin on the 5-microgram dose for people month and then can commence to the 10-microgram dose to additional improve their glycaemic control.

Exenatide has been shown to be effective in clinical trials. Exenatide was loosely kindly tolerated across the trials. The most common adverse anyhow reported was mild to slacken nausea that was dose dependent. With continued remedial programme, the frequency and severity of nausea decreased beyond constantly in most patients. Consistent with exenatide’s self-regulating action, exenatide stimulates the publicity of insulin only when needed, thereby reducing the covert for hypoglycaemia (low blood sugar).

Almost BYETTA

Exenatide is the before in a late-model lineage of medicines known as incretin mimetics and was approved for use in the United States by the U.S. Aliment and Sedative Application in April 2005 as an adjunctive therapy to revive blood sugar control in patients with font 2 diabetes who contain not achieved adequate glycaemic lead on metformin and/or a sulfonylurea, two prosaic oral diabetes medications. Exenatide exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1, secreted in rejoinder to food intake, has multiple effects on the intestine, liver, pancreas and brain that work in concert to regulate blood sugar.(4)

In Incretin Mimetics

Incretin mimetics are a altered discernment of treatment in the fight against diabetes. An incretin mimetic works to imitator the antidiabetic or glucose- lowering actions of inherently occurring human hormones called incretins. These actions allow for stimulating the body’s ability to produce insulin in response to elevated levels of blood sugar, inhibiting the release of a hormone called glucagon following meals, slowing the rate at which nutrients are absorbed into the bloodstream and reducing comestibles intake. Exenatide is the first FDA-approved incretin mimetic.

About Diabetes

Diabetes affects an estimated 194 million adults worldwide(5) and around 48.4 million in Europe.(6) Approximately 90 to 95 percent of those are phoney by personification 2 diabetes, a condition characterized by washout of the pancreatic beta cells to adequately react to to the increased demands for insulin that occur as a effect of obesity-kindred insulin guerrillas.(7) Prototype 2 diabetes usually occurs in adults from the years of 40, but is increasingly general in younger people.(6) In virtually every developed society, diabetes is ranked among the foremost causes of blindness, renal failure and lower limb amputation, as well as death through its effects on cardiovascular condition (70-80 percent of people with diabetes die of cardiovascular disease)(8). The calculated estimates of the costs of diabetes care in Europe amount to 42.8 million International Dollars per year.(9)

About Lilly and Amylin

Through a dream of-standing commitment to diabetes nurse, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier, and fuller lives. Since 1923, Lilly has been the trade leader in pioneering therapies to help health custody professionals take a new lease on life the lives of people with diabetes, and analysis continues on innovative medicines to speak the unmet needs of patients.

Lilly, a greatest modernization-driven corporation is developing a growing portfolio of win initially-in-class and best-in-descent pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent orderly organizations. Headquartered in Indianapolis, IN, Lilly provides answers — past medicines and information — quest of some of the world’s most clamorous medical needs.

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, advancement and commercialization of innovative medicines. Amylin’s into and evolvement activities leverage the company’s expertise in metabolism to develop potential therapies to treat diabetes, obesity and cardiovascular disease. Amylin is located in San Diego, California with beyond 1400 employees.

This Fleet Street manumission contains forward-looking statements about Amylin and Lilly. Current results could differ materially from those discussed or implied in this press release due to a troop of risks and uncertainties, including the chance that exenatide may not prove to be an foremost different therapeutic option, or exenatide may be affected by unexpected unfledged data or technical issues. The potential on exenatide may also be niminy-piminy by government and commercial reimbursement and pricing decisions, the pace of peddle acceptance and any issues related to manufacturing and inventory. These and additional risks and uncertainties are described more fully in Amylin and Lilly’s most recently filed SEC documents such as their Quarterly Reports on System 10-Q. Amylin and Lilly disclaim any obligation to update these forward-looking statements.

P-LLY

REFERENCES

(1) Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Annals of Internal Nostrum. 2005; 143(8):559-69.

(2) Nauck MA, Duran S, Kim D, Johns D, Festa A, Trautmann M. Effects of exenatide compared with twice-common biphasic insulin aspart in patients with typewrite 2 diabetes using sulphonylurea and metformin. Information disclosure at the 42nd annual get-together of the European Association of the Study of Diabetes. September 14, 2006.

(3) Barnett A, Trautmann M, Burger J, Johns D, Kim D, Brodows R, Festa A, Roberts A. A comparability of exenatide and insulin glargine in patients using a choose spoken antidiabetic agent. Data disclosure at the 42nd annual meeting of the European Association of the Study of Diabetes. September 16, 2006.

(4) Kolterman, O, Buse J, Fineman M, Gaines E, Heintz S, Bicsak T, Taylor K, Kim D, Aisporna M, Wang Y, Baron A. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting glucose in subjects with type 2 diabetes. Quarterly of Clinical Endocrinology & Metabolism. 2003; 88(7):3082- 3089.

(5) The International Diabetes Federation Diabetes Atlas. Available at: http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-87B73F80BC22682A. Accessed April 12, 2005.

(6) The International Diabetes Federation, Prevalence / All diabetes. Available at http://www.eatlas.idf.org/Prevalence/All_diabetes/.

(7) Turner RC, Cull CA, Frighi V, Holman RR. Glycaemic control with sustenance, sulfonylurea, metformin, or insulin in patients with standard 2 diabetes mellitus: revolutionary must for multiple therapies (UKPDS 49). JAMA. 1999; 281 (21):2005-2012.

(8) The Cosmopolitan Diabetes Federation, Complications. Available at http://www.eatlas.idf.org/Complications/

(9) The Cosmopolitan Diabetes Federation, Diabetes Atlas, Second edition. The Economic Crash of Diabetes. 2003: 186.

Eli Lilly and Body

http://www.lilly.com/

View drug low-down on Byetta; Glucagon.

Y’s Therapeutics, Inc. said
today that the U.S. Provisions and Drug Supervision (FDA) and the European
Medicines Evaluation Agency (EMEA) cause granted Orphan Hallucinogenic Designation and Orphan Medicinal Product Designation, severally, seeing that its investigational
drug YSPSL (rPSGL-Ig) in the proscribing of graft dysfunction in kidney
transplantation.

“This is an important milestone for Y’s Therapeutics,” stated John
Wulf, President of Y’s Therapeutics, Inc. “Orphan pre-eminence as a service to YSPSL’s lead
indication of Delayed Kickback Serve (DGF) in kidney transplant patients
will assist the YSPSL evolvement and commercialization program. Upon
regulatory approval, this status will lend market exclusivity in return YSPSL
in Europe in compensation ten years and for seven years in the Like-minded States for this
indication.”

In Europe in 2005, more than 17,000 kidney transplant operations took
give, while approximately 16,500 patients received transplants in the U.S.
during the yet period, according to the International Registry of Mouthpiece
Donation and Transplantation. Transplants from non-living donors — to the ground
9,900 in the U.S. form year — are particularly prone to DGF. The
underlying cause of DGF is ischemia-reperfusion injury, which occurs when
blood flow is restored to cells that have planned been hitherto deprived of
oxygen and nutrients. The resulting inflammation worsens the damage and can
follow-up in poor organ go, rejection and earlier graft loss.

YSPSL (rPSGL-Ig) is a promising clinical-originate recombinant molecule
resulting from fusion of P-selectin glycoprotein ligand-1 (PSGL-1) to human
IgG1. It is currently eye evaluation for the prophylaxis of DGF following
kidney transplantation. YSPSL blocks a class of adhesion molecules known as
selectins and prevents the collection of both leukocytes and platelets at
sites of irritation. Specifically, it binds to selectins expressed on
activated platelets and endothelial cells. Consequently, YSPSL inhibits
binding of fomenting cells bearing selectin ligands as favourably as
subsequent inflammatory project, platelet coagulation and thrombosis.
Provision of YSPSL in animal models of transplantation suggests it may
also upregulate anti-apoptotic genes such as hemoxygenase-1 that protect
organs from ischemia- reperfusion injury.

YSPSL has completed extensive End I testing and evaluation in Phase
II studies. A Slant gradually introduce II study in DGF was initiated in November 2005, and is
currently enrolling patients in 14 serious transplant centers in the U.S. The
trial is being managed by CTI, a full waiting specialty CRO with critical
expertise in transplantation clinical trials.

Y’s Therapeutics http://www.ysthera.com/) is a privately held
biopharmaceutical house engaged in the R&D of novel therapeutics for the
treatment of infection-mediated diseases, cancer and other unmet medical
needs. Y’s focuses on the development of preclinical and clinical projects
pursued by way of research collaborations and in-licensing opportunities from
academic institutions and biotech companies. Y’s intends to seek
collaborative relationships, including out-licensing of output rights and
creation of dump ventures, for current-stage maturity, manufacturing and
commercialization of its portfolio products. The company currently has
several projects in its clinical and preclinical pipeline.

Y’s Therapeutics, Inc.

http://www.ysthera.com/